Loading...

Realm Therapeutics

AIM:RLM
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RLM
AIM
£13M
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. The last earnings update was 226 days ago. More info.


Add to Portfolio Compare Print
  • Realm Therapeutics has significant price volatility in the past 3 months.
RLM Share Price and Events
7 Day Returns
-5.7%
AIM:RLM
0.4%
GB Pharmaceuticals
-1.9%
GB Market
1 Year Returns
-71%
AIM:RLM
16.7%
GB Pharmaceuticals
-0%
GB Market
RLM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Realm Therapeutics (RLM) -5.7% 18.3% 35.6% -71% -60.8% -76.5%
GB Pharmaceuticals 0.4% 1.2% 8.2% 16.7% 29.4% 24.4%
GB Market -1.9% -0.3% 9.2% -0% 12.3% 0.6%
1 Year Return vs Industry and Market
  • RLM underperformed the Pharmaceuticals industry which returned 16.7% over the past year.
  • RLM underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -0% over the past year.
Price Volatility
RLM
Industry
5yr Volatility vs Market

RLM Value

 Is Realm Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Realm Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is £0.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Realm Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Realm Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:RLM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in USD $-0.18
AIM:RLM Share Price ** AIM (2019-03-26) in GBP £0.1
AIM:RLM Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.307 $0.13
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry PE Ratio Median Figure of 10 Publicly-Listed Pharmaceuticals Companies 25.24x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 801 Publicly-Listed Companies 15.64x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Realm Therapeutics.

AIM:RLM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:RLM Share Price ÷ EPS (both in USD)

= 0.13 ÷ -0.18

-0.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Realm Therapeutics is loss making, we can't compare its value to the GB Pharmaceuticals industry average.
  • Realm Therapeutics is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Realm Therapeutics's expected growth come at a high price?
Raw Data
AIM:RLM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 2.12x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 569 Publicly-Listed Companies 1.39x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Realm Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Realm Therapeutics's assets?
Raw Data
AIM:RLM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in USD $0.21
AIM:RLM Share Price * AIM (2019-03-26) in GBP £0.1
AIM:RLM Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.307 $0.13
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry PB Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 2.15x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,360 Publicly-Listed Companies 1.47x
AIM:RLM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:RLM Share Price ÷ Book Value per Share (both in USD)

= 0.13 ÷ 0.21

0.63x

* Primary Listing of Realm Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Realm Therapeutics is good value based on assets compared to the GB Pharmaceuticals industry average.
X
Value checks
We assess Realm Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Realm Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RLM Future Performance

 How is Realm Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Realm Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.3%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Realm Therapeutics expected to grow at an attractive rate?
  • Unable to compare Realm Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Realm Therapeutics's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Unable to compare Realm Therapeutics's revenue growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
AIM:RLM Future Growth Rates Data Sources
Data Point Source Value (per year)
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17.3%
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 6.8%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 10.9%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:RLM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:RLM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
AIM:RLM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-06-30 1 -15 -17
2018-03-31 1 -12 -14
2017-12-31 1 -9 -11
2017-09-30 1 -8 -10
2017-06-30 1 -7 -8
2017-03-31 1 -6 -8
2016-12-31 1 -5 -7
2016-09-30 1 -4 -7
2016-06-30 1 -2 -6
2016-03-31 1 -3 -6
2015-12-31 1 -3 -5
2015-09-30 5 -3 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Realm Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Realm Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:RLM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Realm Therapeutics Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:RLM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
AIM:RLM Past Financials Data
Date (Data in USD Millions) EPS *
2018-06-30 -0.18
2018-03-31 -0.17
2017-12-31 -0.16
2017-09-30 -0.17
2017-06-30 -0.17
2017-03-31 -0.16
2016-12-31 -0.15
2016-09-30 -0.13
2016-06-30 -0.12
2016-03-31 -0.11
2015-12-31 -0.10
2015-09-30 -0.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Realm Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Realm Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Realm Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Realm Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Realm Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Realm Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RLM Past Performance

  How has Realm Therapeutics performed over the past 5 years?

  • Realm Therapeutics's last earnings update was 226 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Realm Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Realm Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Realm Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Realm Therapeutics's 1-year growth to the GB Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Realm Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Realm Therapeutics Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:RLM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 0.50 -17.24 5.54 12.60
2018-03-31 0.81 -13.88 4.58 10.39
2017-12-31 1.12 -10.53 3.62 8.19
2017-09-30 1.12 -9.51 3.40 7.28
2017-06-30 1.12 -8.49 3.16 6.40
2017-03-31 1.00 -7.91 3.08 5.72
2016-12-31 0.87 -7.33 3.00 5.05
2016-09-30 0.90 -6.70 3.59 3.81
2016-06-30 0.93 -6.07 4.18 2.56
2016-03-31 1.08 -5.65 4.28 2.18
2015-12-31 1.23 -5.24 4.39 1.79
2015-09-30 5.24 -5.35 5.36 2.03
2015-06-30 9.24 -5.46 6.32 2.28
2015-03-31 13.19 -6.24 8.01 2.38
2014-12-31 17.15 -7.02 9.69 2.48
2014-09-30 39.96 -3.96 13.73 3.04
2014-06-30 27.70 -4.28 10.18 2.45
2014-03-31 29.58 -6.45 10.27 2.36
2013-12-31 31.46 -8.62 10.35 2.27
2013-09-30 38.65 -7.43 12.24 2.73
2013-06-30 34.33 -7.32 11.61 2.77
2013-03-31 40.85 -4.12 12.58 3.38
2012-12-31 47.36 -0.93 13.56 3.99
2012-09-30 48.25 -2.44 13.55 4.16
2012-06-30 49.15 -3.95 13.54 4.33
2012-03-31 45.85 -6.54 14.17 4.36

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Realm Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Realm Therapeutics has efficiently used its assets last year compared to the GB Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Realm Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Realm Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Realm Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RLM Health

 How is Realm Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Realm Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Realm Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Realm Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Realm Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Realm Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Realm Therapeutics Company Filings, last reported 8 months ago.

AIM:RLM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 24.28 0.00 23.67
2018-03-31 24.28 0.00 23.67
2017-12-31 32.20 0.00 33.85
2017-09-30 32.20 0.00 33.85
2017-06-30 15.27 0.00 15.56
2017-03-31 15.27 0.00 15.56
2016-12-31 19.05 0.00 21.43
2016-09-30 19.05 0.00 21.43
2016-06-30 17.77 0.00 12.77
2016-03-31 17.77 0.00 12.77
2015-12-31 19.34 0.00 15.46
2015-09-30 19.34 0.00 15.46
2015-06-30 23.98 0.22 16.55
2015-03-31 23.98 0.22 16.55
2014-12-31 28.36 0.22 20.89
2014-09-30 28.36 0.22 20.89
2014-06-30 31.73 2.23 1.18
2014-03-31 31.73 2.23 1.18
2013-12-31 13.28 0.00 3.44
2013-09-30 13.28 0.00 3.44
2013-06-30 12.26 0.95 4.20
2013-03-31 12.26 0.95 4.20
2012-12-31 -1.41 13.37 2.54
2012-09-30 -1.41 13.37 2.54
2012-06-30 -1.76 14.78 4.72
2012-03-31 -1.76 14.78 4.72
  • Realm Therapeutics has no debt.
  • Realm Therapeutics has no debt compared to 5 years ago when it was 7.6%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Realm Therapeutics has sufficient cash runway for 1.6 years based on current free cash flow.
  • Realm Therapeutics has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 41.3% each year.
X
Financial health checks
We assess Realm Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Realm Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RLM Dividends

 What is Realm Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Realm Therapeutics dividends.
If you bought £2,000 of Realm Therapeutics shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Realm Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Realm Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:RLM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 6 Stocks 4.1%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 702 Stocks 4.3%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.1%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:RLM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Realm Therapeutics has not reported any payouts.
  • Unable to verify if Realm Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Realm Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Realm Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Realm Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Realm Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Realm Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RLM Management

 What is the CEO of Realm Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alex Martin
COMPENSATION $861,600
AGE 50
TENURE AS CEO 3.8 years
CEO Bio

Mr. John Alexander Martin, also known as Alex, has been the Chief Executive Officer and Executive Director of PuriCore Plc since June 12, 2015. Mr. Martin has more than 25 years' experience having held senior positions in both private and public companies principally in the pharmaceutical and biopharmaceutical industry. He has a wealth of strategic, commercial and operational experience. He has successfully developed and launched new products, driven operational improvements, negotiated sizeable licensing arrangements and led successful IPOs and private fundraising initiatives. He served as President of Moksha8 Pharmaceuticals, Inc. from 2012 to 2015 and served as its Senior Vice President of Corporate Development. He joined Moksha8 Pharmaceuticals, Inc. in July 2011. He has been Vice President of Commercial Operations and Business Development at Unigene Laboratories Inc., since November 2010. He served as Managing Director of The Sophocles Group from 2009 to 2011. Previously, Mr. Martin served as Chief Executive Officer, Chief Financial Officer and Chief Business Officer of several dynamic biotech companies. He has raised over $100m from private and institutional investors, completed two successful IPOs, acquired multiple pharmaceutical products and signed 9-figure licensing deals. He served as the Chief Executive Officer and Chief Business Officer of Affectis Pharmaceuticals AG. Mr. Martin served as Chief Financial Officer of Affectis Pharmaceuticals AG. Mr. Martin served as Chief Operating Officer of Intercept Pharmaceuticals, Inc. since May 2007 until 2009 and also served as its Chief Executive Officer, Chief Financial Officer and Chief Business Officer. Mr. Martin served as Chief Financial Officer of BioXell S.p.A. until April 2007 and also served as its Chief Executive Officer. Prior thereto, Mr. Martin served as Vice President, Global Business Development and Licensing of Novartis AG and was responsible for partnering its key assets via co-development and co-commercialisation alliances; additionally he was responsible for out-licensing non-strategic compounds for Novartis. His previous experience includes four years at Medscape LLC as Executive Vice President, Pharmaceutical Sales & Marketing. He also served as Vice President of Sales and Marketing of Medscape LLC. Mr. Martin joined BioXell in January 2003 as Chief Business Officer and was responsible for business development and licensing, as well as for commercial input into R&D processes. Mr. Martin began his career in 1989 at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline), where he took on roles of increasing responsibility in sales, marketing and business development. He worked in five countries. He has been Director of Rasna Therapeutics, Inc. since August 2016. He served as a Member of Supervisory Board of Affectis Pharmaceuticals AG since June 20, 2007. Mr. Martin obtained his BA degree in Government from Cornell University in 1989 and went on to do an MBA at Harvard Business School in 1995.

CEO Compensation
  • Alex's compensation has increased whilst company is loss making.
  • Alex's remuneration is higher than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Realm Therapeutics management team in years:

3.8
Average Tenure
51
Average Age
  • The tenure for the Realm Therapeutics management team is about average.
Management Team

Alex Martin

TITLE
CEO & Executive Director
COMPENSATION
$862K
AGE
50
TENURE
3.8 yrs

Marella Thorell

TITLE
CFO, COO
COMPENSATION
$595K
AGE
51
TENURE
6 yrs

Christian Peters

TITLE
Chief Medical Officer
AGE
56
TENURE
2.9 yrs
Board of Directors Tenure

Average tenure and age of the Realm Therapeutics board of directors in years:

3.8
Average Tenure
53
Average Age
  • The tenure for the Realm Therapeutics board of directors is about average.
Board of Directors

Charles Alexander Spicer

TITLE
Non-Executive Chairman
COMPENSATION
$84K
AGE
53
TENURE
4.8 yrs

Alex Martin

TITLE
CEO & Executive Director
COMPENSATION
$862K
AGE
50
TENURE
3.8 yrs

Marella Thorell

TITLE
CFO, COO
COMPENSATION
$595K
AGE
51
TENURE
6 yrs

Bill Birkett

TITLE
Senior Independent Non-Executive Director
COMPENSATION
$54K
AGE
70
TENURE
11.1 yrs

Simba Gill

TITLE
Non-Executive Director
COMPENSATION
$90K
AGE
53
TENURE
3 yrs

Ivan Gergel

TITLE
Independent Non-Executive Director
COMPENSATION
$73K
AGE
57
TENURE
2.2 yrs

Sandy Zweifach

TITLE
Non-Executive Director
COMPENSATION
$32K
AGE
62
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
21. Feb 19 Buy BAVARIA Industries Group AG Company 20. Feb 19 20. Feb 19 6,944,948 £0.08 £520,873
30. Nov 18 Sell RA Capital Management, LLC Company 29. Nov 18 29. Nov 18 -3,750,000 £0.08 £-299,999
29. Nov 18 Sell RA Capital Management, LLC Company 28. Nov 18 28. Nov 18 -500,000 £0.09 £-45,000
09. Oct 18 Sell RA Capital Management, LLC Company 18. Sep 18 02. Oct 18 -210,000 £0.10 £-18,710
X
Management checks
We assess Realm Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Realm Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RLM News

Simply Wall St News

Should You Worry About Realm Therapeutics Plc's (LON:RLM) CEO Pay Cheque?

Alex Martin became the CEO of Realm Therapeutics Plc (LON:RLM) in 2015. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Alex Martin's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Is Realm Therapeutics Plc's (LON:RLM) Balance Sheet A Threat To Its Future?

Realm Therapeutics Plc (LON:RLM), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is RLM will have to follow strict debt obligations which will reduce its financial flexibility. … Is RLM growing fast enough to value financial flexibility over lower cost of capital.

Simply Wall St -

How Should Investors Feel About Realm Therapeutics Plc's (LON:RLM) CEO Pay?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Alex Martin's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below US$200m.

Simply Wall St -

What Kind Of Risk Should You Expect For Realm Therapeutics Plc (LON:RLM)?

If you're interested in Realm Therapeutics Plc (LON:RLM), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Why Realm Therapeutics Plc's (LON:RLM) Ownership Structure Is Important

In this article, I will take a quick look at Realm Therapeutics Plc’s (AIM:RLM) recent ownership structure – an unconventional investing subject, but an important one. … Insider Ownership Another important group of shareholders are company insiders. … Private Company Ownership Potential investors in RLM should also look at another important group of investors: private companies, with a stake of 6.25%, who are primarily invested because of strategic and capital gain interests.

Simply Wall St -

Is There Now An Opportunity In Realm Therapeutics Plc (LON:RLM)?

Let’s take a look at Realm Therapeutics’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. … And if you believe Realm Therapeutics should be trading in this range, then there isn’t much room for the share price grow beyond what it’s currently trading. … In addition to this, it seems like Realm Therapeutics’s share price is quite stable, which could mean there may be less chances to buy low in the future now that it’s fairly valued.

Simply Wall St -

Realm Therapeutics Plc (LON:RLM): Does -39.96% Earnings Drop In A Year Reflect The Long-Term Trend?

For Realm Therapeutics, its most recent earnings (trailing twelve month) is -US$8.49M, which, relative to last year’s figure, has become more negative. … This means whatever tailwind the industry is benefiting from, Realm Therapeutics has not been able to gain as much as its industry peers.What does this mean? … Though Realm Therapeutics's past data is helpful, it is only one aspect of my investment thesis.

Simply Wall St -

Does Zero-Debt Make Realm Therapeutics Plc (AIM:RLM) A Financially Strong Company?

The direct benefit for Realm Therapeutics Plc (AIM:RLM), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … While RLM has no debt on its balance sheet, it doesn’t necessarily mean it exhibits financial strength. … See our latest analysis for RLM Is RLM growing fast enough to value financial flexibility over lower cost of capital?

Simply Wall St -

Who Owns Realm Therapeutics Plc (AIM:RLM)?

View our latest analysis for Realm Therapeutics AIM:RLM Ownership Summary Nov 6th 17 Institutional Ownership Institutions account for 31.50% of RLM's outstanding shares, a significant enough holding to move stock prices if they start buying and selling in large quantities, especially when there are relatively small amounts of shares available on the market to trade. … Insider Ownership Another important group of shareholders are company insiders. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors.

Simply Wall St -

RLM Company Info

Description

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc was founded in 2016 and is headquartered in Malvern, Pennsylvania.

Details
Name: Realm Therapeutics Plc
RLM
Exchange: AIM
Founded: 2016
£13,404,620
116,561,917
Website: http://www.realmtx.com
Address: Realm Therapeutics Plc
267 Great Valley Parkway,
Malvern,
Pennsylvania, 19355,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM RLM Ordinary Shares London Stock Exchange AIM Market GB GBP 30. Jun 2006
BST 3HD Ordinary Shares Boerse-Stuttgart DE EUR 30. Jun 2006
NasdaqCM RLM SPONSORED ADS Nasdaq Capital Market US USD 05. Jul 2018
Number of employees
Current staff
Staff numbers
15
Realm Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/28 21:41
End of day share price update: 2019/03/26 00:00
Last estimates confirmation: 2018/05/02
Last earnings filing: 2018/08/14
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.